PCOS Is Now PMOS: New Name Aims to Enhance Understanding and Care
In an important shift for women’s health, polycystic ovary syndrome (PCOS) has been officially renamed polyendocrine metabolic ovarian syndrome (PMOS). This change, decided after over a decade of discussions among global experts, aims to better convey the condition’s multisystem effects on the body.
The announcement was made during the European Congress of Endocrinology held in Prague and was also detailed in a recent publication in *The Lancet*. It is estimated that 1 in 8 females worldwide are affected by this hormonal disorder, which has often been misunderstood due to its previous name.
Dr. Sherry Ross, an OB-GYN and women’s health expert, emphasized the misleading nature of the term “polycystic ovary syndrome.” She noted that the new name, PMOS, more accurately reflects the broader impact of the condition, which extends beyond the ovaries. “This updated terminology provides a more inclusive understanding of a medical issue that affects many women,” she stated.
The name change reflects a consensus achieved after extensive collaboration among 56 academic, clinical, and patient organizations, which sought to prioritize a term that accurately represents the condition’s complexity. The selected name highlights three crucial aspects: ovarian, metabolic, and polyendocrine, pointing to the disorder’s wide-ranging effects on various body systems.
Dr. Steven Vasilev, a gynecologic oncologist, reinforced the importance of the new term, explaining that it signals to healthcare providers that PMOS is a condition impacting the entire body, not just a gynecological issue. He noted that by omitting the term “cysts,” which do not appear in all patients, the name provides clarity and reduces confusion regarding the diagnosis.
Historically, the term “polycystic ovary syndrome” has led to delays in diagnosis and care, perpetuating stigma and missing opportunities for early intervention regarding metabolic and cardiovascular risks. Experts believe that the new name addresses these challenges by emphasizing the hormonal and metabolic complexities of the disorder.
The renaming initiative is expected to reshape the way PMOS is diagnosed and treated. Increased awareness of its metabolic and hormonal roots—such as insulin resistance and chronic inflammation—could drive future research and clinical approaches. Dr. Vasilev pointed out that focusing on these underlying issues is crucial for improving patient outcomes.
While it may take time for the medical community and the public to adapt to this change, both Dr. Ross and Dr. Vasilev agree that the transition to PMOS is essential for better understanding and managing what has been described as a complex, multisystem endocrine condition. The hope is that this new terminology will lead to more accurate diagnoses, improved patient care, and a clearer understanding of the condition’s impact on women’s health.
